1857-19-8

Basic information

• Product Name: 2-amino-N,N-dimethylacetamide
• Synonyms: N,N-Dimethyl-2-aminoacetamide;2-diazenyl-N,N-dimethylacetamide;2-Amino-N,N-dimethylacetamide;Glycine dimethylamide, 97%;A80236;N~1~,N~1~-dimethylglycinamide(SALTDATA: HCl);N~1~,N~1~-dimethylglycinamide 1HCl;2-aMino-N,N-diMethylacetaMide hcl
• CAS NO: 1857-19-8
• Molecular Formula: C₄H₁₀N₂O
• Molecular Weight: 102.13
• Mol File: 1857-19-8.mol

Chemical Properties

• Boiling Point: 181.3oC at 760 mmHg
• Flash Point: 63.5oC
• Appearance: /
• Density: 0.995±0.06 g/cm3(Predicted)
• Vapor Pressure: 0.856mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 8.46±0.10(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: 2-amino-N,N-dimethylacetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-N,N-dimethylacetamide(1857-19-8)
• EPA Substance Registry System: 2-amino-N,N-dimethylacetamide(1857-19-8)

Safety Data

• HazardClass: 8
• Hazardous Substances Data: 1857-19-8(Hazardous Substances Data)

Usage

Uses

Glycine dimethylamide is used as pharmaceutical intermediate.

InChI:InChI=1/C4H10N2O/c1-6(2)4(7)3-5/h3,5H2,1-2H3/p+1

Upstream product

• 2185-00-4 1,3-oxazolidine-2,5-dione 
• 124-40-3 dimethyl amine 
• 167303-60-8 N-Benzyloxycarbonylglycine dimethylamide 
• 1138-80-3 N-(Benzyloxycarbonyl)glycine 
• 68-12-2 N,N-dimethyl-formamide 
• 72287-76-4 N-[2-(dimethylamino)-2-oxoethyl]carbamic acid 1,1-dimethylethyl ester 

Downstream Products

• 340011-61-2 N,N-dimethyl-2-[6-phenyl-2-(4-trifluoromethylphenyl)-4-pyrimidinylamino]acetamide 
• 335154-66-0 1-(4-[N-(2-Dimethylamino-2-oxoethylcarbamoyl)aminomethyl]-3-methylbenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 1357917-82-8 2-[(3-methylbenzylidene)amino]-N,N-dimethylacetamide 
• 1357917-83-9 2-[(2-methylbenzylidene)amino]-N,N-dimethylacetamide 
• 1357917-78-2 2-[(4-bromobenzylidene)amino]-N,N-dimethylacetamide 
• 1357917-80-6 2-[(4-methoxybenzylidene)amino]-N,N-dimethylacetamide 
• 1357917-76-0 2-benzylideneamino-N,N-dimethylacetamide 
• 1357917-81-7 2-[(4-nitrobenzylidene)amino]-N,N-dimethylacetamide 
• 1357917-79-3 2-[(4-chlorobenzylidene)amino]-N,N-dimethylacetamide 
• 1357917-77-1 2-[(4-trifluoromethylbenzylidene)amino]-N,N-dimethylacetamide 
• 1357917-87-3 (E,E)-2-[(3-phenylprop-2-en-1-ylidene)amino]-N,N-dimethylacetamide 

Relevant articles and documents

Highly Selective and Sensitive Detection of Biogenic Defense Phytohormone Salicylic Acid in Living Cells and Plants Using a Novel and Viable Rhodamine-Functionalized Fluorescent Probe

Detecting plant-derived signal molecules using fluorescent probes is a key topic and a huge challenge for scientists. Salicylic acid (SA), a vital plant-derived defense hormone, can activate global transcriptional reprogramming to systemically express a network of prominent pathogenesis-related proteins against invasive microorganisms. This strategy is called systemic acquired resistance (SAR). Therefore, monitoring the dynamic fluctuations of SA in subcellular microenvironments can advance our understanding of different physiological and pathological functions during the SA-induced SAR mechanism, thus benefiting the discovery and development of novel immune activators that contribute to crop protection. Here, detection of signaling molecule SA in plant callus tissues was first reported and conducted by a simple non-fluorescent rhodamine-tagged architecture bearing a flexible 2-amino-N,N-dimethylacetamide pattern. This study can markedly advance and promote the usage of fluorescent SA probes for distinguishing SA in the plant kingdom.

Facile Access to the 12-Membered Macrocyclic Ligand PCTA and Its Derivatives with Carboxylate, Amide, and Phosphinate Ligating Functionalities

We describe a convenient synthetic pathway to access the 12-membered PCTA macrocycle, a polyaminocarboxylate ligand for which its M2+ and M3+ complexes are commonly associated with applications in biomedical diagnostics and radiother

Pd-Catalyzed sequential β-C(sp3)-H arylation and intramolecular amination of δ-C(sp2)-H bonds for synthesis of quinolinones: Via an N,O-bidentate directing group

The pharmacological importance of 2-quinolinone derivatives is well known. Herein, we developed an effective protocol for the synthesis of 2-quinolinone derivatives by palladium-catalyzed sequential β-C(sp3)-H arylation and selective intramolecular C(sp2)-H/N-H amination starting with aryl iodides and carboxylic acids. A novel directing group, glycine dimethylamide, was used in the synthesis. We synthesized various quinolinone derivatives, including 5-substituted quinolinones, which are difficult to obtain using the traditional pathway. The directing group could be easily removed and could be readily transformed into other useful functional groups.

Synthesis, physical-chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer's disease

A novel class of 2-amido-3-hydroxypyridin-4-one iron chelators is described. These compounds have been designed to behave as suitable molecular probes which will improve our knowledge of the role of iron in neurodegenerative conditions. Neurodegenerative disorders, such as Alzheimer's disease (AD) and Parkinson disease (PD), can be considered as diverse pathological conditions sharing critical metabolic processes such as protein aggregation and oxidative stress. Interestingly, both these metabolic alterations seem to be associated with the involvement of metal ions, including iron. Iron chelation is therefore a potential therapeutic approach. The physico-chemical (pKa, pFe 3+ and log P) and biological properties (inhibition of iron-containing enzymes) of these chelators have been investigated in order to obtain a suitable profile for the treatment of neurodegenerative conditions. Studies with neuronal cell cultures confirm that the new iron chelators are neuroprotective against β-amyloid-induced toxicity.

IRON MODULATORS

Iron modulator compounds of formula (I) are provided for treating amyloidoses wherein R1 is selected from H, C1-6 alkyl, C1-6 alkenyl, C1-6 hydroxyalkyl, C1-6 hydroxyalkenyl, R2 is selected from H, C1-6 alkyl, C1-6 alkenyl, C1-6 hydroxyalkyl, C1-6 hydroxyalkenyl and C6-10 aralykyl in which the aryl group of the aralkyl group is optionally substituted by hydroxy, halo or C1-4 alkyl R3 is selected from H, C1-6 alkyl, C1-6 alkenyl and C1-12 acyl; R4 is selected from H and C1-3 alkyl R5, R6 and R7 are independently selected from H, C1-6 alkyl, C3-7 aryl, and C1-10 aralkyl; the alkyl, aryl and aralkyl groups being optionally substituted by one or more halo, hydroxy and nitro groups or R5 and R7 together with the nitrogen atom to which they are bonded form a heterocyclic ring optionally substituted by one or more hydroxyl groups or a pharmaceutically acceptable tautomer, ester or addition salt thereof.

Structure-activity relationships of the peptide deformylase inhibitor BB-3497: Modification of the P2′ and P3′ side chains

Structural modifications to the peptide deformylase inhibitor BB-3497 are described. In this paper, we describe the initial SAR around this lead for modifications to both the P2′ and P3′ side chains. Enzyme inhibition and antibacterial activity data revealed that a variety of substituents are tolerated at the P2′ and P3′ positions of the inhibitor backbone. The data from this study highlights the potential for modification at the P2′ and P3′ positions to optimise the physicochemical properties.

Indole derivatives as 5-HT1-like agonists for use in migraine

The present invention relates to 3,5-disubstituted indole compounds which are selective agonists which act on 5-hdroxytryptamine receptors useful in the treatment of migraine.

NITROGEN-SUBSTITUTED MEVINIC ACID DERIVATIVES USEFUL AS HMG-COA REDUCTASE INHIBITORS

Novel nitrogen-substituted mevinic acid derivatives which inhibit the activity of HMG-CoA reductase. Pharmaceutical compositions, and methods of use for the treatment or prevention of hypercholesterolemia, atherosclerosis, hyperlipoproteinaemia and hyperl